key topics
navigation
|
Continuing Medical Education Quiz
Feature:
Continuing Medical Education Quiz
-
| |
Choose the single best answer to the following questions. 1. The general estimate is that more than __ percent of children with JIA will continue to have active arthritis into adulthood. a) 20 b) 40 c) 50 d) 35 2. In regard to the rheumatoid factor negative group with polyarticular JIA, the presentation is often … a) asymmetrical and usually involves the knee and the ankle b) symmetrical and usually involves the small joints of the feet c) symmetrical and often involves both large joints (such as knees, elbows or wrists) as well as small joints in the hands and feet d) None of the above 3. Which of the following are characteristic manifestations of systemic JIA? a) Ulcerative vasculitic rash b) intermittent, spiking fever in excess of 102ºF c) generalized lymphadenopathy and hepatosplenomegaly d) chronic uveitis e) b and c f) a, b and c 4. Which of the following is a true state- ment in regard to JIA-associated uveitis? a) It is asymptomatic in over 80 percent of cases. b) It results in permanent eye damage in at least 15 percent of the involved eyes. c) Eye involvement can develop years after the onset of arthritis or when arthritis is inactive d) It often requires systemic treatment e) a and c f) a,b,c and d 5. The ACR pediatric 50 (ACR Pedi 50) level of response requires … a) 50 percent improvement in at least four of the six core set parameters and no more than one of the parameters can get worse by 50 percent b) 50 percent improvement in at least two of the six core set parameters and no more than two of the parameters can get worse by 30 percent c) 50 percent improvement in at least three of the six core set parameters and no more than one of the parameters can get worse by 30 percent d) 50 percent improvement in at least three of the six core set parameters and no more than one of the parameters can get worse by 50 percent 6. When it comes to the use of naproxen in children with JIA, the side effect of pseudoporphyria is … a) more common in children with fair skin and blond hair b) more common in African-American children c) often totally asymptomatic d) a and c e) b and c f) None of the above 7. In regard to more extensive forms of JIA such as polyarticular JIA … a) NSAID therapy, with or without intraarticular steroid injections, is the mainstay of therapy b) the move to treatments in addition to NSAIDs can occur very early c) one can often adequately treat this with NSAIDs alone d) None of the above 8. In regard to JIA, which of the following NSAIDs have b.i.d. dosing? a) celecoxib b) meloxicam c) naproxen d) a and c e) All of the above 9. Which of the following medications has been the subject of the most studies for JIA? a) etanercept b) celecoxib c) methotrexate d) abatacept 10. The pharmacokinetics and clearance of _____ in children is similar enough to adults to suggest that once-weekly dosing in children would also be effective. a) celecoxib b) etanercept c) infliximab d) naproxen 11. Which of the following is true about the mechanism and dosing of adalimumab for possible use in children with JIA? a) It is a completely humanized, anti-TNF agent that is given subcutaneously every two weeks. b) It is a chimeric monoclonal antibody that patients receive via infusion every month. c) It is an agent with bid dosing that works through a complex, co-stimulatory process that selectively decreases T-cell activation. d) None of the above 12. Pascual and others have demonstrated that systemic JIA, especially with systemic features, is predominantly driven by ______. a) t-cells b) b-cells c) IL-1 and/or IL-6 d) None of the above |
|
| Arthritis Practitioner - ISSN: 1045-7860 - Volume 4 - Issue 1A - April 2008 - Pages: 23 - 23 | |
|
A complimentary CME Webcast Event
To register for this Web Archive program, click on Complimentary CME Webcast Event
This activity is for nurse practitioners, physician assistants, rheumatologists and internal medicine
physicians who treat patients with rheumatoid arthritis (RA).
Panelists/Lectures
"What You Should Know About Treating Early RA"
Nathan Wei, MD
Clinical Director
Arthritis and
Osteoporosis Center
Frederick, Md.
"A Closer Look At The Efficacy And Safety Of Combination Therapy With Anti-TNF Agents"
Philip Mease, MD
Clinical Professor
University of Washington
School of Medicine
Chief, Rheumatology Clinical Research
Swedish Hospital Medical Center
Seattle
"What The Studies Reveal About Emerging Therapies For RA"
Salahuddin Kazi, MD
Chief of Rheumatology
Presbyterian Hospital
Dallas,Tx.
This activity is supported by an educational grant from Genentech and Biogen Idec. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A complimentary CME Webcast Event
ON DEMAND
(Q&A with panelists to follow lectures)
To register for this Webcast program, click on Complimentary CME Webcast
This activity is geared to physicians, rheumatologists, nurses, physician assistants and nurse practitioners who treat rheumatoid arthritis.
Agenda And Faculty
“Treating RA: The Shift To A More Aggressive Therapeutic Approach”
Linda Davis, MHS, PA-C
Assistant Professor
University Of North Texas Health Science Center
“What The Literature Reveals About Combination Therapy”
Kevin M. Latinis, MD, PhD
Division of Allergy, Clinical Immunology and Rheumatology
University of Kansas Medical Center
“New Biologic DMARDs: Can They Have An Impact?”
Salahuddin Kazi, MD
Chief of Rheumatology
Presbyterian Hospital
Dallas, Texas
This activity is supported by an educational grant from Bristol-Myers Squibb. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A complimentary CME Web Archive Event
To register for this Web Archive program, click on Complimentary CME Web Archive Event
This activity is geared to physicians, nurses, physician assistants and nurse practitioners who treat osteoarthritis.
Agenda And Faculty
“A Closer Look At The Role Of Intraarticular Injections”
Frank Caruso, PA-C
Physician Assistant
Wake Forest University Baptist Medical Center
Winston-Salem, NC
“What The Literature Reveals About Viscosupplementation”
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, MD
“Mastering The Technique Of Intraarticular Injections”
Mike Rudzinski, PA-C
Physician Assistant
Buffalo Veterans Affairs Medical Center
Buffalo, NY
This activity is supported by an educational grant from Genzyme. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A Complimentary CME Webcast Event
A Complimentary, On-Demand CME Webcast
To register for this Webcast program, click on Complimentary CME Webcast Event
This activity is geared to physicians, nurses, physician assistants and nurse practitioners who treat rheumatoid arthritis.
AGENDA and FACULTY
"Reviewing The Role of DMARDs In Treating RA"
Don Flinn, PA-C
Physician Assistant, McBride Clinic, Oklahoma City, Ok.
Vice-President, Society Of Physician Assistants In Rheumatology
"Assessing The Potential of Biologic Therapies"
Mark Genovese, MD
Associate Professor of Medicine
Division of Immunology And Rheumatology
Stanford University School Of Medicine
"What You Should Know About Infusion Therapy"
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, Md.
This activity is supported by an educational grant from Bristol-Myers Squibb.
The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
|